Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company exploring new ways to treat dermatological and gastrointestinal diseases, including alternatives to topical steroids.
For decades there have been no new effective treatment options for the disorders Edesa is addressing.
Inhibiting the Inflammation Cascade
We believe that our technology, called sPLA2 inhibitors, will have a superior therapeutic effect because the inflammatory process will be inhibited at its inception rather than after inflammation has occurred.
Allergic Contact Dermatitis
Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. In two clinical studies, this topical therapy has demonstrated significant improvement of multiple symptoms in contact dermatitis patients. Edesa also intends to expand the utility of our sPLA2 inhibitor technology across multiple indications.